Prescribed Sermorelin
Tracing Sermorelin back to its original indication
A short hormone signal with a surprisingly specific medical past. I think the original reason for prescribing it deserves a better hearing.
The original indication
I expected the adult-aging studies to dominate the sermorelin story. Instead, the pediatric papers gave me a much more concrete question: could a child's pituitary release enough growth hormone when prompted? The same peptide could help test the gland's response and, in selected children with growth hormone deficiency, support faster growth. The review of its diagnostic and pediatric treatment roles is a useful place to begin.
An indication is the condition a medicine is intended to treat. In sermorelin's case, the historical approved indication concerned growth hormone deficiency and short stature in children. That specificity appeals to me. A height measurement, a defined deficiency, and a gland whose response can be tested give the discussion something solid to stand on.
Peptide identity: Sermorelin
Sermorelin copies the first 29 amino acids of growth hormone-releasing hormone, or GHRH, a natural signal from the brain. It stimulates the pituitary to release its own growth hormone; downstream, the liver produces more IGF-1, which carries many of growth hormone's effects. The GHRH receptor review describes the receptor and the signaling inside the cell.
The fragment is short enough to disappear from plasma rapidly, yet the hormone response continues after it. The separation between prompt and answer is wonderfully economical biology, to my taste. It also explains why the peptide had a diagnostic use. The mechanism page follows the gland's response, and half-life examines the timing.
Children and older men
In the multicenter study of prepubertal children with growth hormone deficiency, first-year height velocity rose from about 4.1 cm/year to roughly 7-8 cm/year, without excessive IGF-1 generation. In healthy older men studied for 14 days, GHRH(1-29) increased growth hormone and IGF-1. Those are different populations, different questions, and different measurements.
A measured change in a child's growth rate is where I feel the argument becomes persuasive. The adult hormonal response is interesting on its own terms. The Sermorelin research page puts the pediatric growth studies, stimulation tests, and adult work alongside each other, including the tesamorelin trial often drawn into this discussion.
Sermorelin acetate and pharmacy compounding
Sermorelin acetate is the salt form used in the research and in compounded preparations. The peptide is supplied as a freeze-dried powder because solutions can degrade; the storage questions cover the refrigeration language in the research record.
The former approved branded product left the US market in 2008 for commercial reasons rather than a safety or efficacy finding. The clinical review written after its discontinuation records the resulting gap in US growth hormone stimulation testing. Pharmacies compound sermorelin for individual prescriptions within FDA's interim Section 503A framework; that compounded preparation has no FDA approval.
The pharmacy question matters, but so does the purpose attached to the preparation. I give the old pediatric approval a narrow but real significance: it establishes a medical history while adult wellness claims still need their own evidence.